Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

285

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Certolizumab pegol

Subcutaneous (SC) injection

DRUG

Methotrexate

Methotrexate dose between 6 to 8 mg/week.

Trial Locations (8)

Chubu Region

Chugoku Region

Hokkaido Region

Kanto Region

Kinki Region

Kyushu Region

Shikoku Region

Tohoku Region